<SEC-DOCUMENT>0001571049-16-013762.txt : 20160408
<SEC-HEADER>0001571049-16-013762.hdr.sgml : 20160408
<ACCEPTANCE-DATETIME>20160408163148
ACCESSION NUMBER:		0001571049-16-013762
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160408
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160408
DATE AS OF CHANGE:		20160408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				131840497
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36410
		FILM NUMBER:		161563011

	BUSINESS ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
		BUSINESS PHONE:		201-329-7300

	MAIL ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1600975_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT><BR>
<B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>April 8, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phibro Animal Health Corporation</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>01-36410</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>13-1840497</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Glenpointe Centre East, 3rd Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>300 Frank W. Burr Boulevard, Suite 21</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Teaneck, New Jersey</B></P></TD>
    <TD STYLE="width: 34%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>07666-6712</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code:<B> (201) 329-7300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if this
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Item 7.01&nbsp;REGULATION
FD DISCLOSURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 8, 2016, Phibro Animal Health Corporation
(the &ldquo;<U>Company</U>&rdquo;) issued a press release reiterating the safety of Mecadox when used in accordance with the label.
The most recent 12 month sales (through December, 2015) for Mecadox were approximately $15 million. A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information contained in the press release
is being furnished and shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of, or otherwise regarded as filed
under, the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), nor shall it be deemed incorporated by
reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">(d) &nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 11pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 68%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 11pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 11pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 11pt">Press Release, dated April 8, 2016. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: April 8, 2016</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">PHIBRO ANIMAL HEALTH CORPORATION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Thomas G. Dagger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Thomas G. Dagger</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Senior Vice President, General Counsel and Corporate Secretary</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1600975_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro Animal Health Corporation Reiterates Safety of Mecadox&reg;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">TEANECK, N.J., April 8, 2016 (GLOBE NEWSWIRE) &ndash; (NASDAQ:PAHC)
Today, the Food and Drug Administration (FDA) issued a press release stating its intention to take the initial steps in the process
to rescind its approval of Mecadox&reg; (carbadox). Mecadox has been approved and sold in the United States for more than 40 years
and is a widely-used treatment for controlling bacterial diseases including Salmonella and swine dysentery. Mecadox is not used
in human medicine and the class of drug is not considered a medically important antimicrobial. The approved Mecadox label requires
a 42-day withdrawal period pre-harvesting, and to date we have not seen any hazardous residues of carbadox being detected from
pig meat treated in accordance with the approved label.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA approved the original application for Mecadox in the
early 1970s and a supplemental application in 1998, each time as a result of a rigorous safety review. Several years ago, in response
to the availability of more advanced analytical detection methods, the FDA began to raise questions about the persistence of residues
in tissue longer than previously determined. Since that time, Phibro Animal Health has cooperated fully with the FDA&rsquo;s inquiries,
including undertaking comprehensive, rigorous new studies using the latest and most sensitive technology available. Phibro has
been providing the data to the FDA as it is generated, and in accordance with the schedule submitted to the agency, and to date
that evidence has been positive regarding the safety of Mecadox and has reiterated the safety of Mecadox when used in accordance
with the label. As Phibro has told the FDA, our studies are due to be completed in the next 90 days and we expect that the remaining
evidence will support the continued safe use of Mecadox.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Today&rsquo;s
action by the FDA does not prohibit the sale or use of Mecadox in the United States. After 40 years, carbadox remains a highly
effective</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">treatment for controlling bacterial
diseases and swine dysentery. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro has complete confidence in the safety of Mecadox. We
are disappointed that the FDA would take this action when definitive studies are so close to being completed. Under the FDA&rsquo;s
process, we intend to request a hearing and refute the allegations. Phibro will continue to market the product and to vigorously
defend Mecadox based on more than 40 years of science and safe use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">About Phibro Animal Health Corporation</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Phibro Animal Health Corporation is a diversified global developer,
manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry,
swine, cattle, dairy and aquaculture. The company reported net sales of $749 million for the fiscal year ended June 30, 2015. For
further information, please visit www.pahc.com.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Richard Johnson</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer, Phibro Animal Health Corporation</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">+1 201-329-7300</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">investor.relations@pahc.com</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ / "[ P$1  (1 0,1 ?_$ -<   $$ @(#
M      D !P@*!0L$!@$" P$  00# 0$               4&!P@" P0!"1
M  4" P<" @@ "0<-     0(#! 4&!P 1"!(3%!46%PDA&#$C06'1(E,DIPI1
M<3*3)66E)AF18D/6*%@:H4)C1(2DU39F)U>72!$  0($! ($" D(!@<) 0
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M_>'RQSZEO!:6C(2)J6L+HVZI2G)_8Y%4%2UM34%"36]*!T^4RLI)M6$EO"&
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MU5MY6V6TJR:;;:52S94E2E%2I2*B1(3 &),+=VOSMS;#"4!M@&9$YDD<)X#
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M%LFZ8B)44E%F*[DP!D JN#F'U$<?1CNFM+-E[N;32L@!3E*EY?:M[[11/7Q
M\ $1A>7U/W1Y:N 64CP)P$/IX!K.QEX/*!8X9MJ1W%6KAZYO"HBJ0BB?-:1@
MQ8TRJ8AP$HBUJ.=:KE'XE,D AZ@&$/OWN[MH[LZ[1,G:I35/^JXJ:_A0E0\<
M;]NLAZ[-YN" 5? ,/*8GE^Z=O&PJG5/I^LG&O$W![26CF*JJ) @@)F,Y<Z?1
M!@V6R$=E4:?I)%< '(=AP _ <\,;W8;0Y2[6K[RX"!5U:4(/6EE&)'Z[A'BA
M1W:^%U;; _,1,^%1^016^LS;.H+T7AM5:&E62\A4=S;BT=1$0T;D$ZJCFH)Y
MBP.KD7/))HV5464-\")IF,/H XL3=[DQ9K357:J4$T]-3N.J)ZD))\IP':8;
M##2GWD,HQ4M0 \9C;J0,2C 0<-!-CF4;PL5'1+<YPR.=&.9HLTCG#,<C&(B
MC]>/DX^Z7WUOJP4M94?&9Q,B4Y4A(Z!*,KC5&45[/W+MY$K<>.5Q0*+XK:4O
MI=N@Z&(AO!(HY@H-=U750"4H" G2*2FVZ9_H^<&?QQ8#W;K.JX]X?/E,VJ&D
M=<GU*5)I/]<D>"&WNE_2MFGTN+ \0Q/Q1KV>)0_%)_EQ?O(OJ,1Q.+L?[4NT
M 1]H]4U_7+4=NL[A4I:^"?&(&2D;0<$M.S2:*@AM"096KT@, #EM)>OJ'I3+
MWI;L5W6UV%)^YIW'U#M=5D3/]5L_##ZV@Q)EZH/YR@D>(3/QQ;6Q5&'C"P01
MJU?+->E"^?D>U=5VC(D?1;6[,I0, N545$C05LFS2A&8H&S$-RHM!*J!EZ??
M],?3SNKLJ[)W=VFA*2'32)=5^D\2Z?(H#Q1$UX?%1<WG <,\AX$X?DB<?[;F
MT);H>2B"K-5L#N+L5:JO;A.%,LTVTO-(-*!@#F$0R!3>U,N<GTYIB(?##(]X
MJ[&U]W#E&#E=KJIIH=J4DNJ_J"?ACOVPSJW0+Z&T%7PX#XX8SSPWH1O!Y1-1
M:J#U->+M@I2-FXL"+"JDB-#TZT&<33',2E$:GE7HG /0#YX7.XZRKM'=E;DE
M)#E2'*A6'[59R_42GQ1S[@?#]V=D<$23\ Q\I,?7P-6D3O)Y0].Z2B(.8RUY
MZLO)*#EM$0-1%/.RP*BGH(!_>B59"7_. ,8]^5U59^[*XJX.5(;IT]NJL9OJ
M)5'NWV=>[-=2)J^ 8>64-+YA;UHWQ\EFK6KTI$KV,@KD'MC!+ H!T@B;61C&
MB2E1$HB7=&D8ER<,O3,PCA6[I+*JR=W%IHRDAQ=-K*_2?)=^)0C3>G^8NCRY
MS2%91X$X?&(E;^W.M$2ZODTH:I5FW&1-D+=W N>\/N]XDVE%XY*AZ=4.(@)2
M*%D*J,HF/QVDO3U##6]X6ZJM7=J_3@Y7:VH:8':)ZJ_(W(^&.O;3.M=4JZ&T
ME7Y!\<1!\N-Z4;Y>235U6Z4@5]&1]U']NX)?; Y.26O8LJ$:E2$HF+NA<0:Q
MPR$0S,.';W465=D[NK31%)2XJE#JA])XET^10CBO#_,71YR>&>0\"</R1&JQ
M5/:A84D]JBL#%560VEB=H6LJAN+2;()%:V,E-R;UO250/VHH.@&-4?QBI%U#
MHJ-DDQ_,9)GS%QWM^PNEO;-^4U_[HVZVAEPR#R4I!<0#,8R4" "%$^CB(Y:=
M-2F=73@_8D$J&.6? _T\<>-2VK:_.L*X"=UM1]U']S*Q;Q#> BW[Y.(BXJ$@
MVZJCA*)I^"A&L?"0[)1TL=90J")3+K'$Z@F-ZX\VYM2Q[2H/56W:5--1E96H
M#,I2E'#,M2B5*,A(3. P$A'M565%:YK52RMR4O .H 8"#L^"+Q%W$OO>6AM7
ME_Z)EJ3T[VLEF=8V]BJJC5XQ_>>O(I4'--NX^)D$DW)[?4S(ID>KO5$P1D'*
M*:"&VF"QRPAWX][%OL-G?VG87D.[AJD%MTH(4*=I6"P5##56/-"09H22I4CE
M!7]OV9VI?36U"2*5!F)_G'H\0XSZ8#_Y)[TH7ZU\ZM;HI/@=QTU>NKX>!6%;
M?%&G**=%HF"*DI\#(\NIX@ER],A],2YW=65=BV):;64D.(HFU*P_/<&HKZRS
M"+<W^8N+STY@N$#P# ?%!3/VR5HRW"\A,[<I5 KB.L79.JYQ-82@9-"H*\>L
M*)B@S,&0+C$NI(Q<O7(!'Z,1A[R=U-O[OT6X&3E=6MH\*&@7%?6"(5]K,ZMR
M+O0V@GQG#Y8V".*#1(T:]OSU>-F\E@=5=U-45(45.U9ISOO4:UP'57TY%.91
MK;BNIM-,]6TU6B,>DLK!,7TPFH]CGRI2M%DG I"H"J1BC?WN+[Q;/?\ :U+M
MFJ>0UN*A;#0;6H)+S2?NUMS](A,DK2/.!$Y2,XC?<-K?IJQ=6A)-*X<TQ^:3
MQ!ZL<0>$!OTN:L;S:.;N1E\M/59L*4N#%1$Q $?O8N)J2)?0D^BFC*1<K"RJ
M:[%\U7%!-0NT '362(<I@,7$O;FVM9]W6I5DW RIVWK6E4@I2%!23-*DJ3(@
MB9':"0>,(M)6/T3PJ*902Z 1PF)'K$<"L*SOYK-OG4-;3@UI?B^UU)U-Y*%I
MN!=U%44U(J)HL6+&-I^FF*I(Z,8-$4V[5L@BDV:H)E*4"E#/&RCHK'M"R-T3
M&C0V.E;DG.H(0E.))*UG$DS*E$DJ)),>+745M07%9G*A9Z!,GQ#^@BY-X,O"
M?5^F6I6&L+5Q#-(N\Q(IVUM#:-15I)K6N:S;0S63JZL'+8[A@-?OHU<[9LT0
M.H2*;JJ"<XN5,D*@=]W?/1[DIE;0VFLKM!4#45 F \4F8;;!D=($34H@9R!(
M91YSVL%B<I5BMK1)^7FI^;/I/;V='ABT[BK\.V%@@B'5X]3^F2F=1-D])MSF
MR-2W<O,WEY:A8%>B"U9"PJ#%C+.$WM3S#AJYC:1/4*4 ^2CM\)5'YV2Q4P$$
MS"#QL^V-S5.W:W==L):M-&4I=4'--2B2D20D$%S)G25RP3F3/C'"_5TB*INC
M=Q?<G(2F!QXGHG(RZXBA">0WQL5'1;JOH6G8=]3K"IM1-+R"R5EHT'3!QI=I
M3K*ZLL[:'CRK)4^A"*MQC7?J225>()HYF4#)UO=WO>13UHH'G5IJ%-4BQ_$J
MD16N:;"09^GFGG3Q0$J)X1R)N=K4WJ)'F@K'H_LQ-1\$N!Z9B'#6\F>ANU]&
M7ZEN<.:'A].*MG N733&@CPTJE5&H&#CIRWU+4_3D>FB>HJTDV[])%VT;E,J
MV<$.10<DS&*G#NTWO=*R@:RI?>N(J-%9=S)R4JBEU:UF>1L$$I4<%"1'$1L-
MUH&4.*F4AK+F$I&:Q, #I/6(>&1U]:;XJ_=8:;WU1SB%R;?V9E+YUH!J:D>F
M:;I"$B6-02T;)5-ERQ.L8ZGI-M(+Q93&<),W*2A]D#ES1V]A;C=L+.XT-MFV
MU%:FF;\\9UN*44)4E'I:96E2 O@5 @<(WFXTJ:DTI)U4MYSA@ !/CURQEU1V
MZ>U?6>IG2[!:O)U:J(ZT=2TK0-70I7%-NR5B^CKG/X&,HIHG2@J ^YO,O*E9
ME*V$=L@*YFR HY<C&T+Q4[H<VBP&E79IUUM4EC3!9"BX<_#*D(5CV1FJM812
M"M5/1(!&&/G2EAUF8B*ERM;>B"A*VFZ%/9RHKCU\QNK5EIUJ>MEI_8UW-S-;
MT90U,W(KHT61DV*,K'4Q#5FP)(/ /L)OU]P(F4 V'5;=E;WKZ)%<*UNFH%4K
M;X6]5EI*6W'5LM9IGS2M3:BA/2D9N$<;MPH&UEO(5.!93)*)DD *,NN0(GVP
MY\=K*T?4'?J?T_1L5T1=>#L8_OG7#=A;4D"PIBBX6&:U5)T[5E11[1%BTKB)
M@'R,@O"F44<(MEB*F  .413'-G;OK["W?W5Z]J77"F:)>S%;BE%M*VT$DEI2
MP4!R0!((Z#&X5U$W4FF RO!O.?-E( 3D3U@8RALZVUM:1H=]I[=N]-UW*YD]
M7-(Q]P[1NJ5TNK5:\JMM-1:U2K,Y-TFS$[6J(^FD^;2+98YE6C Y5EC !@PI
M46RMVNHN"$7*D8:M#Q9?"ZW3#92K("D3Q05_9H(P4N:1PC4Y<*-):):6HO)S
M)DW.<Q/X98GJ$.S8S5;I'N)5MIH>SU/(,*FO="WKE:,7C+<,:?<*4K8NK6M&
M5S-3CYD@DK$0#ZIEDD8LZP[,D.1TRY!GA*OFU=VV^DJWKPX54U"NF2X"\5C4
MJFRXTE(/I+")E8'H<#&YBLHW5H#(\YP*EYLL$&1)ZA/AUPQZFO+0_)1505JV
ML3<6H*55K1&A* KIAI;?R4%J&N-*5A(4>E2=B)(8<7-S*B=U!&/3#NDTDA;M
M5G(J[D@J"MC8F]VW6Z)5?3MU09U76C6@*I&4MAS4JDYI,H"%)XDF:DIEF,HY
M_65 4E8;649I).G@M4Y21AYQG/X"8QA?*5H1MS!0%;P%!W*BV504;5575JZH
MG3M,EE;34G0MS%[3U6ZO6VA(Y)]132#N*Q68G*N"Q%%D#F2VREVL;#W7[ZN+
M[E#45%,I;;R&VPY5IRON.LA]L4Q49.%3)"L)$ @&48^M[>TD.)2L I),D'S0
M%93FEPDK",W5.O3Q^4M=.L+?UM0CJ!2I:IJ[I6<N]-Z?EC6<>5S;^W:EW*XI
M5I<E*$=1\C5$/1A5'CA#9V]X IB.]$"CII=B=X%5:V:^BJ XIUIIQ-.FK_B
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L^W\P_P"CQ*__ .GT?_J<VG].>EJ_^DR_J9.V$O\ A,W^FX]G&7]?\O9'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
